Study to Evaluate the Efficacy, Safety, and Tolerability of E7070 in Metastatic Breast Cancer Patients
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Sandra Silberman, M.D.
Eisai Inc.
Study Director
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
35 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Facility name not stated
Edmonton, Alberta, Canada
- Facility name not stated
Birmingham, Alabama, United States
- Facility name not stated
Hoover, Alabama, United States
- Facility name not stated
Sedona, Arizona, United States
- Facility name not stated
Denver, Colorado, United States
- Facility name not stated
Torrington, Connecticut, United States
- Facility name not stated
Fort Myers, Florida, United States
- Facility name not stated
Ocoee, Florida, United States
- Facility name not stated
Tampa, Florida, United States
- Facility name not stated
Chicago, Illinois, United States
- Facility name not stated
Skokie, Illinois, United States
- Facility name not stated
Urbana, Illinois, United States
- Facility name not stated
Indianapolis, Indiana, United States
- Facility name not stated
Overland Park, Kansas, United States
- Facility name not stated
Minneapolis, Minnesota, United States
- Facility name not stated
St Louis, Missouri, United States
- Facility name not stated
Albany, New York, United States
- Facility name not stated
Winston-Salem, North Carolina, United States
- Facility name not stated
Kettering, Ohio, United States
- Facility name not stated
Oklahoma City, Oklahoma, United States
- Facility name not stated
Tulsa, Oklahoma, United States
- Facility name not stated
Clairton, Pennsylvania, United States
- Facility name not stated
Pittsburgh, Pennsylvania, United States
- Facility name not stated
Wexford, Pennsylvania, United States
- Facility name not stated
Greenville, South Carolina, United States
- Facility name not stated
Austin, Texas, United States
- Facility name not stated
Dallas, Texas, United States
- Facility name not stated
Fort Worth, Texas, United States
- Facility name not stated
Fredericksburg, Texas, United States
- Facility name not stated
Houston, Texas, United States
- Facility name not stated
Irving, Texas, United States
- Facility name not stated
Tyler, Texas, United States
- Facility name not stated
Fairfax, Virginia, United States
- Facility name not stated
Spokane, Washington, United States
- Facility name not stated
Vancouver, Washington, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 29 Feb 2004
- Primary completion
- —
- Completion
- 31 May 2005
- Last update posted
- 11 Oct 2006
- Registered enrollment
- 250
- Registry id
- NCT00080197
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.